Descriptive Analysis of Everolimus Conversion in Liver Transplant Recipients With Malignant Neoplastic Disease.

•After liver transplant because of hepatocellular carcinoma, patients who do not meet Milan criteria and have vascular microinvasion in the explant have a lower survival.•Malignant neoplasms after solid organ transplant are substantially more frequent than in the general population and remain a major cause of post-transplant mortality.•One of the best-documented associations between immunosuppression and risk of malignant neoplasms is for the calcineurin inhibitor class of drugs.•Everolimus appears to offer a potential option for reducing the risk for hepatocellular carcinoma recurrence after liver transplant and better survival with de novo tumors.